摘要
目的探究安罗替尼胶囊治疗晚期非小细胞肺癌对患者VEGF水平及生存期的影响。方法选取70例晚期非小细胞肺癌患者,随机分成2组,每组35例。对照组采用含铂两药化疗方案治疗,观察组采用安罗替尼胶囊治疗。观察比较2组患者的近期治疗效果,血管内皮生长因子(VEGF)水平,生存期情况以及不良反应情况。结果观察组患者的治疗总有效率为51.43%,对照组为31.43%,差异具有统计学意义(P<0.05)。治疗后观察组患者的VEGF水平为(133.61±34.87)pg/ml,明显低于对照组(230.78±40.62)pg/ml,差异具有统计学意义(P<0.05)。观察组患者的无进展生存期(PFS)、总生存期(OS)明显比对照组长,差异具有统计学意义(P<0.05)。观察组患者的不良反应发生率,包括咯血、咳嗽、呼吸困难、视力模糊、肺感染,与对照组相比,差异没有统计学意义(P<0.05)。结论安罗替尼胶囊在治疗晚期非小细胞肺癌中有一定的优势,能够提高治疗效果,有效降低血清VEGF水平,延长无进展生存期,并不增加不良反应的发生。
Objective To investigate the effect of Anlotinib capsule on the level and survival of vascular endothelial growth factor in advanced non-small cell lung cancer(NSCLC).Methods 70 patients with advanced non-small cell lung cancer were selected and randomly divided into 2 groups,35 cases in each group.The control group was treated,while the observation group was treated with Anlotinib capsule.The short-term therapeutic effect,the level of vascular endothelial growth factor(VEGF),survival time and adverse reactions were observed and compared between the 2 groups.Results The total effective rate of the observation group was 51.43%and that of the control group was 31.43%.The difference was statistically significant(P<0.05).After treatment,the level of vascular endothelial growth factor in the observation group was 133.61+34.87 pg/ml,which was significantly lower than that of the control group(230.78+40.62 pg/ml),and the difference was statistically significant(P<0.05).The PFS and OS of the patients in the observation group were significantly higher than those of the control group(P<0.05).The incidence of adverse reactions in the observation group,including hemoptysis,cough,dyspnea,blurred vision and pulmonary infection,was not significantly different from that of the control group(P<0.05).Conclusion Anlotinib capsule has certain advantages in the treatment of advanced non-small cell lung cancer,which is conducive to improving the therapeutic effect,it can effectively reduce the level of serum vascular endothelial growth factor,increase progression-free survival and reduce the incidence of adverse reactions.
作者
皇甫娟
李文永
张慧辉
HUANG FU Juan;LI Wenyong;ZHANG Huihui(Jiaozuo People's Hospital,Jiaozuo,454000)
出处
《实用癌症杂志》
2020年第3期360-362,共3页
The Practical Journal of Cancer
基金
2017年河南省医药卫生项目计划(编号:172102210006)。
关键词
安罗替尼胶囊
晚期
非小细胞肺癌
VEGF水平
生存期
Anlotinib Capsule
Advanced stage
Non-small cell lung cancer
Level of vascular endothelial growth factor
Survival period
